Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing 681–700 of 2629 stories
The Eunice Kennedy Shriver National Institute of Child Health and Human Development is considering granting an exclusive patent license to EnZeta Immunotherapies, Inc. for innovations related to T cell enhancements. This move could bolster EnZeta's capabilities in developing immunotherapies targeting tumor reactivity.
The FDA has released final guidance on formal dispute resolution and administrative hearings under Section 505G of the Federal Food, Drug, and Cosmetic Act. This guidance aims to clarify procedures for resolving scientific and medical disputes between the FDA and industry stakeholders.
The NIH is seeking public comment on proposed data collection for Loan Repayment Programs, as mandated by the Paperwork Reduction Act. This initiative aims to enhance transparency and gather feedback before submission to the Office of Management and Budget.
The National Cancer Institute (NCI) is seeking public comment on the Clinical Trials Reporting Program (CTRP) database as part of compliance with the Paperwork Reduction Act. This initiative aims to enhance transparency in clinical trial data collection.
The HHS Secretary has accepted the recommendation to add Duchenne Muscular Dystrophy (DMD) to the Recommended Uniform Screening Panel (RUSP), following public comments and evidence-based reports. This decision could enhance early detection and intervention for DMD, impacting patient outcomes significantly.
The Health Resources and Services Administration has recommended adding Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel, a significant step in early detection. This decision follows public comments and evidence-based reports, with the Secretary of Health and Human Services accepting the recommendation.
CMS has established the Office of Rural Health Transformation within the Center for Medicaid and CHIP Services to enhance healthcare delivery in rural areas. This organizational change aims to improve access and quality of care for underserved populations.
The Office of Community Services seeks a 3-year extension for the Community Economic Development Performance Progress Report, with revisions for quarterly reporting. This update aims to enhance data collection and reporting efficiency, expiring on February 28, 2026.
The Agency for Toxic Substances and Disease Registry (ATSDR) is seeking public comment on the proposed National Amyotrophic Lateral Sclerosis (ALS) Registry. This initiative aims to enhance data collection efforts related to ALS, promoting better understanding and support for affected individuals.
The Office of Refugee Resettlement seeks a 3-year extension for the ORR-2 report on Cash and Medical Assistance expenditures, with minor changes proposed. This report is crucial for tracking financial obligations related to refugee assistance programs.
The HHS is undergoing a review under the Paperwork Reduction Act, which may impact data collection processes. This review could affect how agencies manage paperwork and reporting requirements.
The HHS is currently undergoing a review under the Paperwork Reduction Act, which may impact data collection processes. Stakeholders should monitor developments as this could affect reporting requirements.
The National Library of Medicine has announced a partially closed meeting, which may impact future research directions and funding opportunities. Details on the agenda and participants are limited.
The National Institute of Environmental Health Sciences has announced a partially closed meeting, focusing on environmental health research. This meeting may influence future funding and research directions in the field.
The FDA has awarded national priority vouchers to two investigational products aimed at enhancing patient access through affordability. This initiative under the Commissioner’s National Priority Voucher pilot program could significantly impact pricing strategies for new therapies.
The FDA has issued a Request for Information (RFI) to gather insights from venture capital firms on a new contracting approach aimed at enhancing collaboration with innovative companies. This initiative seeks to advance public health innovation through strategic partnerships.
Emer Cooke, EMA's Executive Director, outlines the agency's goals for 2025, focusing on enhancing support for innovation in medicine regulation. The EMA aims to improve early development support for new medicines, benefiting both public and animal health.
The EMA Management Board discussed the political agreement reached among the European Commission, Parliament, and Council regarding regulatory frameworks. This meeting highlights ongoing efforts to streamline drug approval processes in the EU.
EMA will be closed for the holiday period from December 22, 2025, to January 5, 2026. This closure may affect communication and decision-making processes during this time.
FDA releases final guidance on bioresearch monitoring inspections, aligning with the Food and Drug Omnibus Reform Act of 2022. This guidance outlines the processes and practices for inspecting sites and facilities under the Bioresearch Monitoring program.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.